Molecular Partners Ag (MOLN) Return on Assets (2021 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Return on Assets of 14.62% for Q1 2026, down 1462.0% year-over-year from 1.07% in Q1 2025, and down 25.21% quarter-over-quarter from 11.67% in Q4 2025.
Molecular Partners Ag (MOLN) Return on Assets (2021 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Return on Assets for 6 consecutive years, with 14.62% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Assets fell 1462.0% year-over-year to 14.62%; the TTM figure through Mar 2026 stood at 14.62% (down 1462.0% YoY), while the FY2025 annual figure was 0.01%, down 1.0% from the prior year.
- Return on Assets eased to 14.62% in Q1 2026 per MOLN's latest filing, from 11.67% in the prior quarter.
- Across five years, Return on Assets topped out at 0.0% in Q1 2023 and bottomed at 14.62% in Q1 2026.
- Historically, Return on Assets has averaged 2.07% across 5 years, with a median of 0.0% in 2024.
- Annual changes were most pronounced in 2022 — Return on Assets changed 0 bps — and 2026, when it tumbled 1462 bps.
- Molecular Partners Ag's Return on Assets stood at 0.0% in 2022, then slumped by 186 bps to 0.0% in 2023, then climbed by 4 bps to 0.0% in 2024, then tumbled by 167027647 bps to 11.67% in 2025, then dropped by 25 bps to 14.62% in 2026.
- Business Quant data shows MOLN's Return on Assets at 14.62% in Q1 2026, 11.67% in Q4 2025, and 8.87% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 0.00% |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 0.00% |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | -13.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.62% |
| Dec 31, 2025 | -11.67% |
| Sep 30, 2025 | -8.87% |
| Jun 30, 2025 | 0.00% |
| Mar 31, 2025 | 0.00% |
| Dec 31, 2024 | 0.00% |
| Sep 30, 2024 | 0.00% |
| Jun 30, 2024 | 0.00% |
| Mar 31, 2024 | 0.00% |
| Dec 31, 2023 | 0.00% |
| Sep 30, 2023 | 0.00% |
| Jun 30, 2023 | 0.00% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 0.00% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | 0.00% |
| Mar 31, 2022 | 0.00% |
| Dec 31, 2021 | 0.00% |